Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
NCT02349503Phase 1Withdrawn
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2015
- Primary completion
- Oct 2015
- Countries
- 1
01
Overview
Phase 1, open-label trial of verucerfont in congenital adrenal hyperplasia (CAH) (3 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Adverse Events at 8 weeks. Planned start Feb 2015; status: withdrawn.
02
Drugs
verucerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT02349503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349503.